Targeted radiation tested to improve leukemia transplant safety

NCT ID NCT03467386

Summary

This early-stage study is testing a new, more targeted form of radiation given before a stem cell transplant for patients with acute myeloid leukemia (AML) in remission. The goal is to see if focusing radiation only on the bone marrow and lymph nodes, instead of the whole body, is safe and can help control the cancer while reducing side effects. After the transplant, patients receive a drug (cyclophosphamide) to help prevent complications. The study will closely monitor patients for side effects and how well they recover.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

Conditions

Explore the condition pages connected to this study.